Vitamin D3 Supplementation: An Option Associated with The Treatment of Multiple Sclerosis:
A Systematic Review and Meta-Analysis
DOI:
https://doi.org/10.31686/ijier.vol8.iss5.2363Keywords:
Vitamin D3, Multiple Sclerosis, Neurogenesis, Supplementation, DeficiencyAbstract
Multiple sclerosis (MS) is a chronic complex neurodegenerative disease. A systematic review and meta-analysis were conducted on observational studies and analytics on impact of Vitamin D supplementation in patients with Multiple Sclerosis. In our research, a total of 457 articles were selected and identified for analysis. This systematic review article and meta-analysis, which included evidence from randomized controlled trials conducted with patients with multiple sclerosis, revealed that Vitamin D3 supplementation is effective as an option associated with the treatment of this disease, and that it also has a diffuse protective role against various remission outbreaks in the health. Doses (50,000 IU/week) are appropriate to restore neuroimmunological parameters when used within 12 weeks.
Downloads
References
HOLICK MF, 2007. Vitamin D deficiency. The New England Journal of Medicine. 357, 3, p.266-81.
CALLEGARO D, GOLDBAUM M, MORAIS L, TILBERY CP, MOREIRA MA, GABAI AA et al, 2001. The prevalence of multiple sclerosis in the city of São Paulo, Brazil. Acta Neurol Scand. 104, 4, 208-13.
FRAGOSO YD, PEREIRA M, 2007. Prevalence of multiple sclerosis in the city Santos, SP. Rev Bras Epidemiol. 10, 4, 479-82.
MOHER D, LIBERATI A, TETZLAFF J, ALTMAN DG, 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement – PRISMA. Group. Plos Med. Jul, 21, 6(7).
ZIPITIS CS, AKOBENG AK, 2008. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Archives of Disease Childhood. 93, 512-517.
JAGANNATH VA, FILIPPINI G, DI PIETRANTONJ C, ASOKAN GV, ROBAK EW, WHAMOND L, ROBINSON SA, 2018. Vitamina D para el tratamento de la esclerosis múltiple. Cochrane Data bases Rev.
ADORINI L, PENNA G, 2008. Control of autoimmune diseases by the vitamin D endocrine system. Nature Clinical Practice Rheumatology. 4. 404-412.
BJELAKOVIC G, GLUUD LL, NIKOLOVA D, WHITFIELD K, WETTERSLEV J, SIMONETTI RG, BJELAKOVIC, M, GLUUD C, 2014. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database of Systematic Reviews. 7.
SANTOS CMC, PIMENTA CAM, NOBRE MRCN, 2007. A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Revista latino americana de enfermagem. 15. 3.
DE-LA-TORRE-UGARTE-GUANILO MC, TAKAHASHI RF, BERTOLOZZI MR, 2011. Revisão sistemática: noções gerais. Revista da Escola de Enfermagem USP. 45. 5. 1260 - 1266, out.
WHITEHOUSE AJ, HOLT BJ, SERRALHA M, HOLT PG, KUSEL MM, HART PH, 2012. Maternal serum vitamin D levels during pregnancy and offspring neurocognitive development. Pediatrics. 129. 3. 485–93.
VELDMAN CM, CANTORNA MT, DELUCA HF, 2000. Expressão do receptor 1,25-dihidroxivitamina d (3) no sistema imune. Arco. Biochem. Biofísica. 374. 334-338.
ZMUDA JM, CAULEY JA, FERRELL RE, 2000. Molecular epidemiology of vitamin D receptor variants. Epidemiol Rev. 22. 203–17.
KHATKHATAY MI, 2004. Genetic factors contributing to osteoporosis: Study of vitamin D receptor polymorphism and estrogen receptor gene in Indian population. Hum Mol Genet. 15. 1633–9.
THAKKINSTIAN A, EISMAN J, ATTEIA J, NEYGYEN J, 2004. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J Bone Miner Res. 19. 3. 419–28.
HARRIS SS, ECCLESHALL TR, GROSS C, DAWSON-HUGHES B, FELDMAN D, 1997. The vitamin D receptor starts codon polymorphism (FokI) and bone mineral density in premenopausal American black and white women. J. Bone Miner Res. 12. 1043–8.
LISKERR, LOPEZ MA, JASQUI SPD, LEON RS, CORREA RR, SANCHEZ S, MUTCHINICK OM, 2003. Association of vitamin D receptor polymorphisms with osteoporosis in Mexican postmenopausal women. Hum Biol. 75. 3. 399–403.
KESBY JP et al, 2011. The effects of vitamin D on brain development and adult brain function. Mol. Cell Endocrinol. 5. 347. 121- 7.
ROLF L, MURIS AH, MATHIAS A, PASQUIER RD, KONEEZNY I, DISANTO G, KUHLE J, RAMAGOPALAN S, DAMOISEAUX J, SMOLDERS J, HUPPERTS R, 2017. Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. 0. 01-08.
KOVEN NS, CADDEN MH, SANGITA-MURALI BS, ROSS, MK, 2013. Vitamin D and long-term memory in multiple sclerosis. Cogn. behave neurol. 26. 03. 155-160.
ROLF L, MURIS AH, THEUNISSEN R, HUPPERTS R, DAMOISEAUX J, SMOLDERS J, 2018. Vitamin D3 supplementation and IL-02/IL-2R pathway in multiple sclerosis: attenuation of progressive disturbances? Journal of Neuroimmunology. 314. 50-57.
HOLMOY T, LINDSTROM CJ, ERIKSEN EF, STEFFENSEN, LH, KAMPMAN MT, 2017. High dose Vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – randomized controlled trial. BMC Neurology. 17. 67. 01-06.
COCCO E, MELONI A, MURRU MR, CORONGIU D, TRANQUILLI S, FADDA E, MURRUR, SCHIRRU L, SECCI MA, COSTA G, ASUNIS I, FENUG, LOREFICEL, CARBONI N, MURA G, OSATELLI MC, MARROSU MG, 2012. Elements responsive to vitamin D in the HLA-DRB1 promoter region in the alleles associated with multiple sclerosis in Sardinia. PloSOne. 07. 07. e41678.
CHAUDHURI JR, MRIDLULA KR, UMAMAHESH M, BALARAJU B, BANDARU S, 2018. Association of serum 25-hydroxyvitamin D in multiple sclerosis: a study from India. Neurological disorders and stroke international. 01. Issue 01. Article 1006.
SLAVOV GS, MANOVA MG, TRENOVA AG, KOSTADINOVA II, PAVLOV NG, MATEVA ZZ, 2015. Hydroxyvitamin D and Cytokines in multiple sclerosis. Folia médica. 57. 200-206.
HASHEMI R, MORSHEDI M, JAFARABADI et al, 2018. Anti-inflammatory effects ofdietary Vitamin D3 in patients with multiple sclerosis. Neurology Genetics. 04. 6. 01-08.
ROLF L, DAMOISEAUX I, HUITINGA I, KIMENAI D, OUWELAND JVD, RAYMOND H, SMOLDERS J, 2018. Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis. Frontiers in Neurology. 09. Issue. 283. 01-08.
SMOLDERS J, HUPPERTS R, BARKHOF F, GRIMALDI LME, HOLMOY T, KILLESTEIN J, RIECKMANNP, SCHLUEP M, VIETH R, HOSTALEK U, GHAZI-VISSER L, BEELKE M, 2011. SOLAR, study Group. Efficacy of Vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A phase II, multicenter double-blind, randomized, placebo-controlled trial. Journal of Neurological Sciences.
RABEAH AAT, ANWAR AE, AHMAD AS, RAED AR, FAHD AM, 2015. The association of Vitamin D receptor polymorphisms with multiple sclerosis in a case-control study from Kuwait. PlosOne. 05.
KOUCHAKI E, AFARINI M, ABOLHASSANI J, MIRHOSSEINI N, BAHMANI F, MASOUD S, ASEMI Z, 2018. High-dose ω-3 Fatty Acid Plus Vitamin D3Supplementation Affects Clinical Symptoms and Metabolic Status of Patients with Multiple Sclerosis: A Randomized Controlled Clinical Trial. The Journal of Nutrition.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Eliza Miranda Ramos, Matheus Dullius de Lima, Jéssica Eloy Cunha Gonzalez, Gilberto Gonçalves Facco, Francisco José Mendes dos Reis, Elaine S. de P. Melo, Valter Aragão do Nascimento
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyrights for articles published in IJIER journals are retained by the authors, with first publication rights granted to the journal. The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author for more visit Copyright & License.
